Literature DB >> 23550993

Molecular lesions in B-cell lymphoproliferative disorders: recent contributions from studies utilizing high-throughput sequencing techniques.

Piers A Blombery1, Michael Dickinson, David A Westerman.   

Abstract

Next-generation sequencing techniques are powerful high-throughput methods that have enabled the comprehensive documentation of genetic lesions in numerous hematological malignancies. In recent times, the genomes of multiple different B-cell lymphoproliferative disorders including chronic lymphocytic leukemia, diffuse large B-cell lymphoma, Burkitt lymphoma, splenic marginal zone lymphoma, mantle cell lymphoma, hairy cell leukemia and Waldenström macroglobulinemia have been documented. Between them, these studies have reinforced and provided insight into the mechanisms for the dysregulation of known pathways (e.g. nuclear factor-κB [NF-κB]), uncovered the importance of new pathways for oncogenesis (e.g. mRNA processing), identified disease-defining mutations and provided meaningful new targets which are already being translated into therapeutic interventions. This review summarizes the molecular lesions that have been discovered in B-cell lymphoproliferative disorders thus far by studies utilizing high-throughput sequencing techniques and the aberrations in the numerous intracellular pathways that have been shown to be involved.

Entities:  

Mesh:

Year:  2013        PMID: 23550993     DOI: 10.3109/10428194.2013.792112

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Precision medicine in diffuse large B-cell lymphoma: hitting the target.

Authors:  Joost S Vermaat; Steven T Pals; Anas Younes; Martin Dreyling; Massimo Federico; Igor Aurer; John Radford; Marie José Kersten
Journal:  Haematologica       Date:  2015-08       Impact factor: 9.941

Review 2.  Gene mutations and actionable genetic lesions in mantle cell lymphoma.

Authors:  Makhdum Ahmed; Leo Zhang; Krystle Nomie; Laura Lam; Michael Wang
Journal:  Oncotarget       Date:  2016-09-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.